Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
Crossref DOI link: https://doi.org/10.1007/s00213-016-4295-9
Published Online: 2016-06-08
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kinoshita, Toshihiko
Bai, Ya-Mei
Kim, Jong-Hoon
Miyake, Mutsuo
Oshima, Nobuyuki
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.
Meiji Seika Pharma Co., Ltd.
License valid from 2016-06-08